DIAGNOS Inc. DGNOF
0.25 USD 0.00 (+0.00%)
At closeNov 4, 2026, 4:00 PM EST
0.2498 Day range 0.2545
0.13 52-week range 0.38
- YTD
- -3.85%
- 1 year
- +19.05%
- Market cap
- 30.26M
- EPS (ttm)
- -0.03
- YTD return
- -3.85%
- 1-year return
- +19.05%
- Volume
- 34.50K
- Avg volume
- 98.99K
- Open
- 0.2543
- Previous close
- 0.25
- Day's range
- 0.2498 – 0.2545
- 52-week range
- 0.13 – 0.38
2Y +0.0198 (+8.61%)
Earnings
| Report date | Quarter ending | EPS estimate | EPS reported | Surprise | Surprise % |
|---|---|---|---|---|---|
| Nov 21, 2024 | Sep 1, 2024 | 0.00 | -0.01 | — | — |
| Aug 21, 2024 | Jun 1, 2024 | 0.00 | -0.01 | — | — |
| Jul 17, 2024 | Mar 1, 2024 | 0.00 | -0.01 | — | — |
| Feb 28, 2024 | Dec 1, 2023 | 0.00 | -0.01 | — | — |
| Nov 28, 2023 | Sep 1, 2023 | 0.00 | -0.01 | — | — |
| Aug 24, 2023 | Jun 1, 2023 | 0.00 | -0.01 | — | — |
News
DIAGNOS Provides an Update on Stock Warrants 
DIAGNOS Advances Regulatory Strategy with US FDA Submission for CARA System 
DIAGNOS to Hold its Annual General Meeting of Shareholders on September 30, 2026 
DIAGNOS Receives Saudi FDA Medical Device License for CARA System, Bringing AI-Assisted Retinal Image Analysis to Saudi Arabia 
DIAGNOS Receives Health Canada Medical Device Licence for CARA System, Bringing AI-Assisted Retinal Image Analysis to Canadian Optometrists 
DIAGNOS to Extend the Exercise Period of Stock Warrants 
Emerging Growth Research Releases Flash Report on DIAGNOS, Highlighting Regulatory Catalysts and Commercialization Potential for CARA AI Platform 
DIAGNOS to Present at the Emerging Growth Conference on June 10, 2026 
DIAGNOS Announces Amendment to Convertible Debentures 
DIAGNOS Provides an Update on Sales and Regulatory Activities for CARA
Your note
Sign in to keep a note on DGNOF — it syncs with the Stock Master app.